Memorial Sloan Kettering Cancer Center

Iomab-B showed higher durable complete remission rates vs conventional care in relapsed/refractory AML patients, meeting SIERRA study's primary endpoint. Despite positive results, FDA requires another randomized study for Iomab-B approval, citing potential confounding from crossover patients.

Nomic and PICI collaborate to profile ~3000 blood samples from RADIOHEAD study using nELISA™ to understand immunotherapy responses, aiming to improve patient care through precision medicine.

Heavily pretreated ES-SCLC patients benefited from ifinatamab deruxtecan (I-DXd), with a 12 mg/kg dose showing higher overall response rate (54.8%) vs. 8 mg/kg (26.1%). Disease control rates were over 80% in both groups, suggesting I-DXd's potential as a treatment option for ES-SCLC.

Quad countries launch a cancer initiative in the Indo-Pacific, focusing on cervical cancer prevention, detection, and treatment. The initiative aims to improve health infrastructure, expand research collaborations, and support cancer care through various commitments from governments and non-government organizations.

Immunotherapy benefits 20% of cancer patients, with 'hot' tumors (melanoma, non-small cell lung cancer) responding better than 'cold' ones (pancreatic, brain, prostate). Strategies to convert cold to hot tumors include bispecific antibodies and adoptive cell therapy, showing potential in refractory cases like melanoma and small cell lung cancer.

Iomab-B, a CD45 targeted radiotherapy, demonstrated durable Complete Remission and Event-Free Survival in the SIERRA trial for relapsed/refractory AML patients, but did not meet overall survival endpoint due to high crossover rate. Actinium seeks a strategic partner for further U.S. development.

LifeLine Pilots, operating since 1981, offers free flights for medical travel via volunteer pilots, benefiting cancer patients and clinical trial participants. Over 350 pilots flew nearly 1,000 flights in 2022, covering distances from 100 to 1,000 miles. Patients like Cassie and Aiden, who needed long-distance treatment, found relief in this service, which is crucial for health equity and reducing transportation barriers to care.

The FDA expanded approval of Kisqali, a CDK4/6 inhibitor, for early-stage HR-positive, HER2-negative breast cancer, reducing recurrence risk by 28.5% after four years when combined with endocrine therapy. This approval broadens access to a broader patient group compared to similar drugs like Verzenio, which is limited to high-risk cases. The cost of Kisqali over three years is approximately $300,000-$400,000, but insurance coverage is expected to increase.

The FDA expanded approval of Novartis' Kisqali for early-stage breast cancer, reducing recurrence risk by 25% after 3 years and 28.5% after 4 years. Available for HR-positive, HER2-negative cases, it broadens treatment options beyond high-risk patients. However, the cost is high, potentially $300,000-$400,000 over 3 years.

Long-term Phase II PHAROS trial data show Pfizer’s Braftovi (encorafenib) and Mektovi (binimetinib) combo sustained efficacy in BRAF V600E-mutant metastatic NSCLC, positioning it as a promising first-line therapy. The combination demonstrated a 75% objective response rate (ORR) in treatment-naïve patients, with a median duration of response (DoR) of 40 months and median progression-free survival (PFS) of 30.2 months. Safety profile consistent with previous findings, with common treatment-related adverse events (TRAEs) including nausea, diarrhea, and fatigue. The combo was approved by the FDA in October 2023 and the European Commission in August 2024.